Lung Cancer News

CHICAGO — Patient-defined value is the key ingredient missing from a variety of frameworks in cancer care, Janet Freeman-Daily, said during a keynote address at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

MADRID — Nivolumab alone or in combination with ipilimumab as second- or third-line treatment demonstrated encouraging activity in patients with malignant pleural mesothelioma, according to results of a noncomparative randomized phase 2 trial presented at the European Society for Medical Oncology Congress.

MADRID — CT scan-based follow-up provided no significant survival benefit for patients who underwent complete resection for non-small cell lung cancer, according to results of a randomized phase 3 trial presented at the European Society for Medical Oncology Congress.

MADRID — The addition of durvalumab to nab-paclitaxel slightly improved PFS and also improved response rates among patients with nonsquamous non-small cell lung cancer, according to results of a comparative study presented at the European Society for Medical Oncology Congress.

MADRID — The addition of pembrolizumab to pemetrexed and carboplatin for first-line therapy extended survival and improved response rates among previously untreated patients with advanced nonsquamous non-small cell lung cancer, according to study results presented at the European Society for Medical Oncology Congress.

MADRID — First-line osimertinib prolonged PFS by 54% compared with standard therapy among patients with EGFR-positive advanced non-small cell lung cancer, according to results of the FLAURA trial presented at the European Society for Medical Oncology Congress.

HemOnc Today presents nine updates in lung cancer that may affect your practice and how you treat your patients.

Men who reported long-term, high-dose supplementation with vitamins B6 or B12 appeared two to four times more likely than nonusers to develop lung cancer, according to results of a prospective, observational study.

Blood assays identified EGFR mutations in patients with advanced non-small cell lung cancer with insufficient tumor biopsies, according to a prospective analysis published in Annals of Oncology.

An updated ASCO clinical practice guideline clarifies the appropriate use of immunotherapy and provides new recommendations on the use of targeted therapy for patients with stage IV non-small cell lung cancer.